Search research articles
Contact Us
Filters
Showing results (201-210 of 214) with videos related to
Page
of 22
Sort By:
Journal of Hematology & Oncology
|
October 24, 2025
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia
Ashley Varkey, Manpreet Bariana, Mark Batistick, et al.
Cancer
|
April 4, 2003
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases
Francis J Giles, Maureen A Cooper, Lewis Silverman, et al.
Blood Advances
|
April 25, 2020
Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias
Xing Fan, Ronan Desmond, Thomas Winkler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia
Francis Giles, David Rizzieri, Judith Karp, et al.
Blood
|
January 5, 2017
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E Ahn, Chingiz Underbayev, Adam Albitar, et al.
Blood
|
March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Francis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
Blood Advances
|
April 24, 2020
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia
Nicholas J Short, Keyur P Patel, Maher Albitar, et al.
Haematologica
|
December 1, 2020
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome
Alana Vicente, Bhavisha A Patel, Fernanda Gutierrez-Rodrigues, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
Karen W L Yee, Anne Hagey, Srdan Verstovsek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
Hagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 214) with videos related to
Sort By:
Page
of 22
Journal of Hematology & Oncology
|
October 24, 2025
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia
Ashley Varkey, Manpreet Bariana, Mark Batistick, et al.
Cancer
|
April 4, 2003
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases
Francis J Giles, Maureen A Cooper, Lewis Silverman, et al.
Blood Advances
|
April 25, 2020
Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias
Xing Fan, Ronan Desmond, Thomas Winkler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia
Francis Giles, David Rizzieri, Judith Karp, et al.
Blood
|
January 5, 2017
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E Ahn, Chingiz Underbayev, Adam Albitar, et al.
Blood
|
March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Francis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
Blood Advances
|
April 24, 2020
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia
Nicholas J Short, Keyur P Patel, Maher Albitar, et al.
Haematologica
|
December 1, 2020
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome
Alana Vicente, Bhavisha A Patel, Fernanda Gutierrez-Rodrigues, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
Karen W L Yee, Anne Hagey, Srdan Verstovsek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
Hagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Page
of 22